Shares of Chugai Pharmaceutical Co. (OTCMKTS:CHGCY) were up 0.2% on Monday . The company traded as high as $193.38 and last traded at $192.87, approximately 3,470 shares were traded during trading. An increase of 17% from the average daily volume of 2,967 shares. The stock had previously closed at $192.40.
Separately, Jefferies Financial Group assumed coverage on shares of Chugai Pharmaceutical in a research note on Monday, December 9th. They set a “buy” rating on the stock.
About Chugai Pharmaceutical (OTCMKTS:CHGCY)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research and development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and transplant, immunology, infectious, and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra.
Further Reading: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.